Physician profile
Anthony M Tello
NPI 1558469916
$15,219.05
in general payments reported to CMS, 2019-2025
46 companies · $2,603 in 2025
The $2,603 reported for 2025 was more than what 89% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $731 · 2020: $90.36 · 2021: $175 · 2022: $274 · 2023: $2,193 · 2024: $9,153 · 2025: $2,603.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $6,081 · Travel and Lodging: $4,409 · Food and Beverage: $3,449 · Gift: $8.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $6,081.18 |
| Travel and Lodging | $4,409.08 |
| Food and Beverage | $3,449.29 |
| Gift | $8.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $9,954.93 | 2023-2025 | Da Vinci Surgical System |
| Olympus Corporation of The Americas | $1,527.01 | 2024 | Single Use Suction Valve (Sterile) |
| Astrazeneca Pharmaceuticals LP | $430.69 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Abbvie INC. | $364.98 | 2021-2025 | Teflaro, Avycaz, Viberzi |
| Inspire Medical Systems, INC. | $247.26 | 2023-2025 | Inspire |
| Amgen INC. | $206.15 | 2019-2025 | Tavneos, Tezspire |
| Merck Sharp & Dohme LLC | $201.27 | 2019-2025 | Dificid, Zerbaxa, Recarbrio |
| Regeneron Healthcare Solutions, INC. | $199.25 | 2022-2025 | Dupixent |
| Harmony Biosciences LLC | $157.49 | 2022-2024 | Wakix |
| Grifols USA, LLC | $120.59 | 2019-2024 | Xembify, Prolastin-C Liquid |
| Melinta Therapeutics, LLC | $113.23 | 2021-2024 | Orbactiv, Kimyrsa, Rezzayo |
| Pfizer INC. | $111.13 | 2022-2024 | |
| Janssen Biotech, INC. | $107.94 | 2019-2025 | Tremfya, Stelara, Remicade |
| United Therapeutics Corporation | $104.74 | 2022-2025 | Tyvaso, Tyvaso |
| Insmed, INC. | $101.54 | 2024-2025 | Arikayce |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $100.43 | 2023-2025 | Acthar |
| Glaxosmithkline, LLC. | $94.44 | 2022-2025 | Nucala, Shingrix, Trelegy Ellipta |
| Baxter Healthcare | $90.98 | 2023-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Qol Medical, LLC | $78.93 | 2023-2025 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $72.96 | 2019-2025 | Glassia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.96 | 2019 | |
| Allergan, INC. | $63.63 | 2019-2020 | |
| Ucb, INC. | $60.14 | 2019 | |
| Genzyme Corporation | $59.30 | 2024-2025 | |
| La Jolla Pharmaceutical Company | $54.43 | 2022-2023 | Giapreza |
| Mylan Specialty L.P. | $44.40 | 2019-2024 | Yupelri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.67 | 2019-2023 | Xifaxan |
| Mallinckrodt Enterprises LLC | $40.52 | 2019 | |
| Phathom Pharmaceuticals, INC. | $37.99 | 2024-2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $34.52 | 2023-2024 | Xarelto |
| Astellas Pharma US INC | $34.31 | 2019-2020 | |
| Sandoz INC. | $33.55 | 2024 | Hyrimoz |
| Lilly USA, LLC | $32.33 | 2019-2025 | Mounjaro |
| Actelion Pharmaceuticals US, INC. | $31.71 | 2019-2024 | Opsumit, Uptravi |
| Intercept Pharmaceuticals, INC. | $30.69 | 2023-2024 | Ocaliva |
| Viatris Specialty LLC | $20.51 | 2025 | Yupelri |
| Jazz Pharmaceuticals INC. | $20.06 | 2025 | |
| Sanofi-Aventis U.S. LLC | $19.11 | 2021 | |
| Phadia US INC. | $18.07 | 2021 | |
| Davol INC. | $16.17 | 2025 | Arista |
| Pharmacosmos Therapeutics INC. | $13.07 | 2023 | Monoferric |
| Celgene Corporation | $12.91 | 2022 | |
| Shire North American Group INC | $12.23 | 2019 | |
| Genentech USA, INC. | $11.94 | 2019 | |
| Advanced Respiratory, INC | $11.94 | 2019 | |
| Veran Medical Technologies, INC. | $8.95 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Tello listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.